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ABSTRACT 
BACKGROUND 
Myocardial fibrosis, identified by late-gadolinium-enhancement cardiovascular magnetic resonance 
(LGE-CMR), predicts outcomes in chronic heart failure (HF). Its prognostic significance in new-onset 
HF and reduced left ventricular ejection fraction (HF-REF) is unclear. We investigated whether the 
pattern and extent of fibrosis predicts survival in new-onset HF-REF of initially uncertain etiology.  
METHODS AND RESULTS 
Of 120 consecutive patients with new-onset (<6months) HF-REF, 31 (26%) had infarct fibrosis, 25 
(21%) had midwall fibrosis, and 64 (53%) had no fibrosis. During median follow-up of 8.9 years, 33 
(28%) patients died. Patients with infarct fibrosis (HR 3.32; 95% CI 1.46-7.58; P=0.004) or midwall 
fibrosis (HR 2.99; 95% CI 1.24-7.19; P=0.014) were more likely to die compared to those without 
fibrosis. On multivariable analysis, the pattern and extent of fibrosis were both associated with all-
cause mortality (by fibrosis pattern: infarct: HR 2.60; 95% CI 1.08-6.27; P=0.033; midwall: HR 2.64; 
95% CI 1.08-6.47; P=0.034; by fibrosis extent per 1%: HR 1.07; 95% CI 1.03-1.12; P<0.001). 
Fibrosis pattern also predicted composites of cardiovascular mortality or aborted sudden cardiac death 
(SCD) (infarct: HR 3.45; 95% CI 1.20-9.90; P=0.022; midwall: HR 6.59; 95% CI 2.26-19.22; 
P<0.001), and all-cause mortality, HF hospitalization or aborted SCD (infarct: HR 2.69; 95% CI 1.26-
5.76; P=0.011; midwall fibrosis: HR 2.97; 95% CI: 1.37-6.45; P=0.006). Addition of fibrosis pattern 
to LVEF improved risk prediction for all-cause mortality (LVEFvs.LVEF+fibrosis C-statistic: 
0.66vs.0.71; P=0.033). Importantly, the absence of fibrosis heralded a favorable prognosis with an 
85% survival rate over the duration of follow-up. 
CONCLUSIONS 
The pattern and extent of myocardial fibrosis predict adverse outcomes in new-onset HF-REF. In 
contrast the absence of fibrosis portends a durable warranty period with a low incidence of adverse 
events. These findings support a role for LGE-CMR in the early risk-stratification of patients with HF 
of uncertain etiology.  
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INTRODUCTION 
Heart failure (HF) is a major cause of morbidity and mortality worldwide,1 with a particularly poor 
prognosis in the period immediately following diagnosis.2 Early risk stratification is important, with 
implications for initial treatment and intensity of follow-up. However, there remains a dearth of 
validated prognosticators in new-onset HF, with the majority of risk prediction tools derived from 
cohorts of patients with chronic HF.3-5 Current risk stratification is heavily reliant on left ventricular 
ejection fraction (LVEF),6 but the limitations of this approach are well-documented.7, 8  
In patients with new-onset HF and reduced LVEF (HF-REF), one of the principal aims of initial 
evaluation is to distinguish between ischemic and non-ischemic etiologies. Late-gadolinium 
enhancement cardiovascular magnetic resonance (LGE-CMR) allows non-invasive detection of 
myocardial fibrosis,9 and can help to differentiate between ischemic HF and non-ischemic dilated 
cardiomyopathy (DCM). Whereas patients with HF due to ischemic heart disease typically display a 
subendocardial or transmural pattern of myocardial fibrosis indicating previous myocardial infarction, 
patients with DCM either have no fibrosis or a characteristic midwall pattern.9 Our group has already 
shown that LGE-CMR can refine and redefine diagnosis of HF etiology in newly presenting patients, 
thereby serving as a clinically robust and cost-effective gatekeeper to coronary angiography.10 
However, its role in the risk stratification of new-onset HF has not been elucidated. 
Recent international guidelines suggest that assessment of myocardial fibrosis by LGE-CMR may aid 
risk stratification in selected HF patients.11 Both the presence and extent of myocardial fibrosis on 
LGE-CMR predict adverse outcomes in HF patients, but specifically in those with chronic HF due to 
established ischemic 12-15 and non-ischemic etiologies.16-19 There has not yet been any dedicated study 
of the prognostic implications of myocardial fibrosis in patients with a new diagnosis of HF-REF, in 
whom the underlying etiology is initially unclear. Therefore, we evaluated the prognostic significance 
of myocardial fibrosis in patients presenting with new-onset HF-REF of uncertain etiology. 
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METHODS 
The data, analytic methods, and study materials will not be made available to other researchers for 
purposes of reproducing the results or replicating the procedure. 
Patients 
The study prospectively enrolled 124 consecutive patients with new-onset HF (symptom onset < 6 
months before CMR scan), who were referred from 6 designated HF clinics during a 2-year period. 
This cohort was included in an earlier report but we now present a new analysis with clinical follow-
up.10 All patients were diagnosed with HF-REF according to standard criteria.20 Exclusion criteria 
included any prior known history of IHD (previous myocardial infarction or coronary 
revascularization), angina or significant valvular disease. Patients with contraindications to LGE-
CMR were also excluded. Four patients were excluded after enrolment (two patients were unable to 
complete CMR examination due to claustrophobia, one patient was found to have aortic regurgitation 
not identified by echocardiography, one patient withdrew consent). The final cohort therefore 
comprised 120 patients with HF of unknown etiology and no clinical evidence of IHD. After 
recruitment, patients underwent coronary angiography as part of their routine clinical workup to 
identify significant coronary artery disease (>50% luminal stenosis in the left main vessel or >75% 
stenosis in either the proximal left anterior descending artery or ≥2 epicardial vessels).21 The study 
was approved by the local ethics committee and all participants provided written informed consent. 
 
CMR protocol 
Cine images (Siemens Sonata 1.5T [n=42] and Siemens Avanto [n=78]) were acquired with a steady-
state, free-precession, breathhold sequence (echo time/repetition time 1.6/3.2ms; flip angle 60°) in 
standard long-axis planes and sequential contiguous 7-mm short-axis slices (3-mm gap) from the 
atrioventricular ring to the apex. LGE imaging was performed 10 minutes after intravenous 
gadolinium-DTPA (Schering 0.1mmol/kg) in identical long- and short-axis planes using an inversion-
recovery gradient echo sequence. Inversion times were adjusted to null normal myocardium (typically 
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280-380ms; voxel size 1.7x1.4x8.0mm) and images were obtained in 2 separate phase-encoding 
directions to exclude artifact. 
 
CMR analysis 
Images were analysed with semi-automated software (CMR Tools, Cardiovascular Imaging Solutions, 
London). A single blinded experienced reader measured right and left ventricular volumes, LVEF and 
left ventricular mass, using standard techniques.22, 23 Ventricular volumes and left ventricular mass 
were indexed to body surface area. The presence and pattern of myocardial fibrosis was determined 
by a separate panel of 3 expert cardiologists blinded to all clinical data. Myocardial fibrosis was 
judged to be present in areas of LGE, which were visible in both phase encoding directions and two 
orthogonal views. Patients were categorized as having infarct fibrosis (subendocardial or transmural 
LGE in the distribution of a coronary artery perfusion territory), midwall fibrosis (LGE confined to 
the intramural and/or subepicardial layers without subendocardial involvement in any myocardial 
segment), or no fibrosis (Figure 1). In patients with infarct or midwall fibrosis, an independent reader 
quantified fibrosis extent as a percentage of left ventricular mass, using the full-width half-maximum 
technique (CMR42, Circle Cardiovascular Imaging).24  
 
Clinical follow-up and end-points 
Follow-up data was collected prospectively at 6 monthly intervals for all patients. Clinical events 
were ascertained through direct patient contact by telephone interview and postal questionnaires, 
review of clinical correspondence from cardiologists/family practitioners, and examination of medical 
records following hospitalization.  Survival status was established at each follow-up interval from the 
UK Health and Social Care Information Service. Cause of death was ascertained from collective 
review of information provided by death certification, medical records for in-hospital deaths, and 
post-mortem results where available. No patient was lost to follow up. 
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The predefined primary end-point was all-cause mortality. Two secondary composite, time-to-first 
event, end-points were also pre-specified: 1) cardiovascular (CV) death or aborted SCD (SCD); 2) all-
cause mortality, HF hospitalization or aborted SCD. CV death was defined as death due to HF, SCD, 
myocardial infarction, or thromboembolic event. Aborted SCD was defined as an appropriate 
implantable cardiiverter defibrillator (ICD) shock for ventricular arrhythmia, a non-fatal episode of 
ventricular fibrillation, or sustained ventricular tachycardia (>30s) causing hemodynamic compromise 
and requiring cardioversion. HF hospitalization was defined as a hospital admission with signs and 
symptoms of decompensated HF requiring intravenous HF treatment (diuretics, vasodilators and/or 
inotropes). 
 
Statistical analysis 
Continuous data are expressed as mean values±standard deviation, or medians with interquartile range 
as appropriate. The baseline characteristics of study population, stratified by fibrosis pattern, were 
compared by Kruskal-Wallis test for continuous variables, and Chi-squared test for categorical 
variables. Survival estimates were constructed by the Kaplan-Meier method. The log-rank test was 
used to compare the Kaplan-Meier survival curves. Univariable Cox proportional hazards models 
were used to analyse the relationship between baseline covariables and end points, with results 
presented as hazard ratios (HRs) and 95% confidence intervals (CIs). The association between fibrosis 
pattern/extent and outcome was evaluated in a multivariable Cox model adjusting for established 
prognostic variables including age, sex and LVEF. The proportional hazards assumption was tested 
and verified for each covariable on the basis of Schoenfield residuals. The impact of using fibrosis 
pattern or extent as well as LVEF to predict risk of all-cause mortality, compared to using LVEF 
alone, was assessed via the change in Harrell’s C-Statistic using a non-parametric bootstrap approach 
to test the significance of the change. Stata version 15 (StatCorp, College Station, Texas) was used for 
all statistical analyses. A 2-tailed P value of <0.05 was considered statistically significant. 
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RESULTS 
Study Population 
One hundred and twenty patients with new-onset HF were enrolled, of whom 31 (26%) had infarct 
fibrosis, 25 (21%) had midwall fibrosis, and 64 (53%) had no fibrosis. The median extent of infarct 
fibrosis was 4.4% (interquartile range [IQR] 1.5-7.4) and the median extent of midwall fibrosis was 
2.4% (IQR 1.3-4.3). No patient had co-existent infarct and midwall fibrosis. The median duration of 
HF at the time of enrollment was 59 days (IQR 33-88 days). Table 1 shows the baseline 
characteristics of the study population stratified by fibrosis pattern. There were no significant 
differences in age, HF duration, functional status, CMR measures of left ventricular (LV) size and 
function, and prescription of disease-modifying HF medicines between the three groups at the time of 
CMR scanning. Patients with infarct fibrosis were more likely to receive aspirin and statin therapy at 
enrolment and have significant coronary artery disease. 
 
Follow-up data 
Event data are summarized in Table 2. Patients were prospectively followed for a median period of 
8.9 years (IQR 8.3-9.5 years). During this period 35 (29%) patients had a device implanted, including 
7 ICDs, 11 cardiac resynchronization therapy (CRT) pacemaker devices, and 17 CRT-defibrillators. 
Seventeen (14%) patients had coronary revascularization; eight had percutaneous coronary 
interventions (PCI), 8 had coronary artery bypass surgery (CABG), and 1 patient had both. There 
were 33 deaths during follow-up, of which 21 (64%) were cardiovascular, including 9 SCDs, 11 due 
to HF, and 1 death due to acute myocardial infarction. Twenty (17%) patients were hospitalized for 
HF and 6 (5%) patients had an aborted SCD.  
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Primary End Point: All-cause mortality 
Overall, there were 33 deaths, involving 13/31 (41.9%) with infarct fibrosis and 10/25 (40.0%) 
patients with midwall fibrosis. In contrast, only 10/64 (15.6%) patients with no fibrosis died during 
this period (Table 2). Kaplan-Meier survival curves demonstrated an association between fibrosis 
pattern and all-cause mortality (Figure 2A; Figure IA in Data Supplement). On univariable 
analysis, patients with infarct fibrosis (hazard ratio [HR], 3.32; 95% confidence interval (CI), 1.46-
7.58; P=0.004) and midwall fibrosis (HR, 2.99; 95% CI, 1.24-7.19; P=0.014) were more likely to 
reach the primary end point than those with no fibrosis (Table 3). In the multivariable model that 
included LVEF, age and sex, both infarct and midwall fibrosis remained significantly associated with 
all-cause mortality (infarct: HR, 2.60; 95% CI, 1.08-6.27; P=0.033; midwall: HR, 2.64; 95% CI, 1.08-
6.47; P=0.034; Table 4). The percentage extent of fibrosis was also independently associated with the 
primary endpoint (HR, 1.07; 95% CI, 1.03-1.12, P=<0.001) (Table 4). The prognostic significance of 
both fibrosis pattern and extent was retained on multivariable analysis after further adjustment for 
coronary revascularization or device implantation (Table I in Data Supplement). Addition of 
fibrosis assessment to a baseline model incorporating LVEF improved Harrell’s C-statistic from 0.66 
to 0.71 for fibrosis pattern (95% CI of difference 0.003-0.14; P=0.033), and 0.66 to 0.71 for fibrosis 
extent (95% CI of difference 0.00-0.14; P=0.051). 
 
Secondary End Points 
The secondary composite end point of CV death or aborted SCD occurred in 27 (23%) patients 
(Table 2), with a higher event rate among patients with infarct or midwall fibrosis (Figure 2B; 
Figure IB in Data Supplement), and only 4 CV deaths and 1 aborted SCD in the subgroup with no 
fibrosis. After adjusting for LVEF, age and sex, both fibrosis pattern (infarct: HR, 3.45; 95% CI 1.20-
9.90; P=0.022; midwall: HR, 6.59; 95% CI, 2.26-19.22; P<0.001) and extent (HR, 1.06; 95% CI, 
1.02-1.10, P=0.005) were independently associated with this outcome (Table 4).  
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The secondary composite end point of all-cause mortality, HF hospitalization or aborted SCD, was 
reached by 43 (36%) patients (Table 2). Kaplan-Meier estimates of event-free survival again showed 
a significant difference in this outcome according to fibrosis pattern (Figure 2C; Figure IC in Data 
Supplement). Fibrosis pattern also predicted this outcome in the multivariable model (infarct fibrosis; 
HR, 2.69; 95% CI, 1.26-5.76; P=0.011; midwall fibrosis; HR, 2.97; 95% CI 1.37-6.45; P=0.006; 
Table 4), as did fibrosis extent (HR, 1.05; 95% CI, 1.01-1.09; P=0.008). 
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DISCUSSION 
We found that the detection of myocardial fibrosis by LGE-CMR, either with infarct or midwall 
pattern, was associated with an increase in all-cause mortality amongst patients with new-onset HF-
REF of initially undetermined etiology. The prognostic value of fibrosis was independent of LVEF, 
one of the most important and clinically relevant prognostic markers in current practice. Both the 
pattern and extent of fibrosis were also predictive of composite outcomes comprising CV mortality or 
aborted SCD, and all-cause mortality, aborted SCD or HF hospitalisation. Importantly, the absence of 
fibrosis at baseline conferred a favorable long-term prognosis with low rates of major adverse 
cardiovascular events. Furthermore, the combination of fibrosis pattern with LVEF improved risk 
prediction for all-cause mortality. These findings suggest that detection and quantification of fibrosis 
constitute valuable markers for early risk stratification in HF-REF irrespective of underlying etiology.  
 
A growing body of observational evidence suggests that non-invasive fibrosis assessment by LGE-
CMR constitutes a powerful tool for risk stratification in both ischemic and non-ischemic chronic 
HF.25, 26 However, the vast majority of studies to date have focused on populations with established 
and well-characterized disease.12-19 Patients with new-onset HF of initially uncertain etiology 
represent a distinct group that is frequently encountered in clinical practice. Such patients are at 
particularly high-risk in the early phase of their disease course, with a mortality rate 3 to 4-fold higher 
in the first year after diagnosis compared to subsequent years.27-29 During the same ‘high-risk’ period, 
decisions regarding CRT and/or ICD implantation may be deferred for up to 3 months pending 
initiation and titration of guideline-directed medical therapy. Robust and accurate methods for risk 
stratification in patients with new-onset HF-REF may therefore facilitate greater individualization of 
treatment, enabling more aggressive strategies in patients with poorer prognosis at an earlier stage in 
their clinical course.  
 
Guideline recommendations on HF treatment depend on measurement of LVEF, which is also used to 
stratify risk.30, 31 However, LVEF often improves spontaneously or as a consequence of therapy in the 
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months following diagnosis, which may limit its prognostic utility. In one study of patients with 
recent-onset HF and severe ventricular dysfunction (LVEF<30%), 43% of participants demonstrated 
LV recovery to mildly impaired or normal function within 6 months.32 Similarly, among patients with 
severe non-ischemic cardiomyopathy undergoing ICD implantation within 6 months of diagnosis, 
59% no longer met guideline criteria for ICD insertion at 12 months, predominantly due to recovery 
of LVEF to ≥35%.33 Prediction of outcome based solely on LVEF is therefore challenging in the early 
stages of HF when patients are also at the highest risk of adverse events. Similar limitation also 
applies to other prognostic variables such as New York Heart Association functional class, natriuretic 
peptides and renal function, all of which are liable to considerable fluctuation in the first year of 
treatment. In contrast to these dynamic indices, which may be useful for gauging response to therapy, 
fibrosis exhibits less variability over time.34 Moreover, the presence and extent of fibrosis evaluated 
by LGE-CMR have been shown to determine the likelihood of LV reverse remodeling following 
therapy in patients with HF due to ischemic and non-ischemic etiologies.34-38 Such observations 
reinforce the logical premise that dysfunctional myocardium with replacement fibrosis is less 
amenable to recovery than regions without fibrosis. We limited our investigation to patients with 
recently diagnosed HF-REF, a substantial proportion of whom might be expected to experience LV 
reverse remodeling with optimal treatment. Our findings highlight the prognostic value of LGE-CMR 
in this group, and suggest that myocardial fibrosis assessment may serve as a more stable and durable 
marker of risk in the early stages of HF after diagnosis. 
 
A number of mechanisms may underpin the relationship between fibrosis and adverse outcomes. It is 
well recognized that myocardial fibrosis provides a substrate for ventricular re-entrant arrhythmia and 
hence SCD.39, 40 In addition, since myocardial fibrosis is closely linked to the likelihood of reverse 
remodeling, it may provide a marker of the severity of the intrinsic pathologic processes driving 
ventricular dysfunction and HF progression. Infarct fibrosis has been shown to correlate with the 
underlying burden of coronary artery disease and may therefore also signify overall atherosclerotic 
risk.12  
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We found that myocardial fibrosis detection offered independent and incremental prognostic 
information for all-cause mortality. These findings accord with previous studies of LGE-CMR. 
Amongst 61 patients with advanced HF due to new-onset non-ischemic DCM, midwall fibrosis 
detected by LGE-CMR was a strong predictor of subsequent death or the need for cardiac 
transplantation or mechanical circulatory support.41 The presence of fibrosis was also associated with 
a range of adverse cardiovascular outcomes in two further cohorts of patients with suspected non-
ischemic cardiomyopathy of recent onset.42, 43 Although these studies support the potential prognostic 
value of LGE-CMR in the early evaluation of HF, they were limited by small sample sizes and / or 
short duration of follow-up, leading to reliance on broad composite endpoints. In contrast, the 
prolonged follow-up and greater number of events in the present study allowed us to demonstrate the 
prognostic impact of fibrosis on overall survival alone, as well as important non-fatal events. Perhaps 
the most remarkable finding from our study was the ability of LGE-CMR to identify a cohort of HF-
REF patients with a low long-term risk of adverse cardiovascular outcomes. In patients without CMR 
evidence of fibrosis, overall survival over a median of 9 years was 85%. Indeed, there were 
numerically more deaths due to non-cardiovascular causes in the subgroup without myocardial 
fibrosis, reflecting the increased exposure to competing risks that accrues with improved survival. 
 
In the diagnostic work-up of HF, ischemic LV dysfunction is conventionally distinguished from DCM 
by the presence of >50% stenosis in one or more epicardial coronary arteries.44 Previous work by our 
group has questioned the validity of this simple dichotomous approach and formed the basis for a 
more refined etiologic classification informed by myocardial fibrosis assessment using LGE-CMR, in 
addition to luminal angiography.10 The present study now establishes the prognostic implications of 
these tissue characterization findings. Historically, HF of ischemic etiology has been associated with a 
poorer prognosis than non-ischemic cardiomyopathy. Yet we observed that the risk of all-cause 
mortality and adverse cardiovascular outcomes among DCM patients with midwall fibrosis was at 
least equivalent to patients with prior infarction. These findings concur with a previous investigation, 
which showed that patients with DCM who exhibited midwall fibrosis had a similar risk of adverse 
events to those with ischemic cardiomyopathy following CRT implantation, whilst DCM patients 
Gulati et al: Fibrosis in New-Onset HF  
13  
without fibrosis had a far superior prognosis.45 Moreover in the present study, the extent of fibrosis 
(irrespective of pattern) predicted outcome, suggesting that the burden of myocardial scar is an 
important prognostic factor regardless of HF etiology. 
 
Such observations are of particular interest in light of recent evidence from the DANISH trial that has 
questioned the benefit of prophylactic ICD implantation in DCM.46 The lack of observed benefit from 
ICD implantation in that trial (which did not use LGE-CMR to select patients) has been attributed, in 
large measure, to the more favorable prognosis of DCM compared to ischemic cardiomyopathy.47 
Although the present study was not powered to study the impact of fibrosis on SCD per se, it clearly 
suggests that LGE-CMR may be able to identify a subset of DCM patients with an adverse prognosis 
and an overall risk profile akin to ischemic cardiomyopathy. The potential contribution of LGE-CMR 
to stratification of SCD risk in non-ischemic cardiomyopathy has recently been recognized in major 
international guidelines.11 Given the strong prognostic signal demonstrated in this and other studies, 
prospective trials are now warranted to examine whether fibrosis imaging can improve clinical 
outcomes in HF by guiding prophylactic ICD implantation.48 
 
Study limitations 
The study population size and event rate limited the number of candidate covariables we could 
include in our multivariable model. In addition, several well-established prognostic factors in HF, 
including renal function and natriuretic peptide levels, were not systematically recorded in all patients 
and not included in our analyses. Further work in larger cohorts is required to assess the incremental 
value of fibrosis over these and other markers both individually, and as part of validated multivariable 
prognostic scoring systems. We acknowledge that a single tertiary centre CMR unit has the potential 
to attract referral bias. However, we tried to minimize the risk of this by enrolling consecutive patients 
with newly presenting HF-REF at 5 additional secondary care institutions without in-house CMR. Our 
study cohort consisted predominantly of patients with mild to moderate HF in sinus rhythm and 
without clinical features suggestive of IHD. Whilst the population has broad relevance to clinical 
practice, our findings may not be applicable to patients with more severe or advanced HF. In 
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particular the rate of SCD or aborted SCD in our cohort was relatively low, reflecting the spectrum of 
disease severity and high rates of contemporary medical therapy. LGE-CMR detects focal regions of 
replacement fibrosis. Patients with HF-REF may also exhibit diffuse interstitial fibrosis. Emerging 
CMR T1-mapping techniques were not in routine clinical use at the inception of the study, but may 
allow quantification of interstitial fibrosis. 
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Conclusions 
In patients with HF of recent onset and uncertain etiology, the detection of infarct pattern or midwall 
myocardial fibrosis by LGE-CMR provides prognostic information independent of that provided by 
age, sex and LVEF, and improves risk stratification for all-cause mortality. These findings provide an 
additional rationale for LGE-CMR in this clinical setting beyond its established diagnostic utility. 
Further study is now required to explore whether changes in management based on knowledge of 
fibrosis pattern and extent for patients with new-onset HF-REF can improve outcomes. 
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CLINICAL PERSPECTIVE 
Risk stratification of patients with new-onset heart failure and reduced left ventricular ejection 
fraction (HF-REF) is challenging because many established prognostic markers, including left 
ventricular ejection fraction (LVEF), are liable to change substantially in response to guideline-
directed heart failure therapies. Identification of more stable and durable markers of long-term risk in 
the initial months following diagnosis may help guide the use of more intensive treatment strategies, 
such as device therapy, at an earlier stage in disease trajectory. Myocardial fibrosis, identified by late 
gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR), has previously been 
shown to predict outcomes in established HF-REF. In this study, we show that myocardial fibrosis 
assessment by a single baseline LGE-CMR in patients with new-onset HF-REF provides powerful 
prognostic information over a protracted period. Even after adjustment for LVEF, patients with 
myocardial fibrosis, in either an infarct or midwall pattern, had a 2 to 3-fold increased risk of all-
cause mortality. The absence of fibrosis portends a significant warranty period, with an 85% survival 
rate over a median of 9-years follow-up observed in our cohort. Our findings provide evidence that 
LGE-CMR could help to inform decision-making in new-onset HF-REF patients regarding advanced 
HF therapies and treatments for other major co-morbidities.  
 
Gulati et al: Fibrosis in New-Onset HF  
18  
References 
 
1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC and 
Grobbee DE. The epidemiology of heart failure. European Heart Journal. 1997;18:208-225. 
2. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA and 
Sutton GC. Survival of patients with a new diagnosis of heart failure: A population based 
study. Heart. 2000;83:505-510. 
3. Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB, Swedberg K, 
Dobson J, Poppe KK, Whalley GA and Doughty RN. Predicting survival in heart failure: A 
risk score based on 39 372 patients from 30 studies. European Heart Journal. 2013;34:1404-
1413. 
4. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, 
Greenberg BH, Yancy CW, Young JB and Fonarow GC. Predictors of mortality after 
discharge in patients hospitalized with heart failure: An analysis from the organized program 
to initiate lifesaving treatment in hospitalized patients with heart failure (optimize-hf). 
American heart journal. 2008;156:662-673. 
5. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, 
Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL and Packer M. The 
seattle heart failure model: Prediction of survival in heart failure. Circulation. 
2006;113:1424-1433. 
6. Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA 3rd, Ferguson 
TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka 
MJ, Stevenson LW, Stevenson WG and Varosy PD. 2012 accf/aha/hrs focused update 
incorporated into the accf/aha/hrs 2008 guidelines for device-based therapy of cardiac rhythm 
abnormalitiesa report of the american college of cardiology foundation/american heart 
Gulati et al: Fibrosis in New-Onset HF  
19  
association task force on practice guidelines and the heart rhythm society. Circulation. 
2012;126:1784-1800. 
7. Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, Portnay EL, 
Marshalko SJ, Radford MJ and Krumholz HM. The association of left ventricular ejection 
fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll 
Cardiol.2003;42:736-742. 
8. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, 
Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, 
Massie BM, Carson PE and Investigators ftI-P. Mode of death in patients with heart failure 
and a preserved ejection fraction: Results from the irbesartan in heart failure with preserved 
ejection fraction study (i-preserve) trial. Circulation. 2010;121:1393-1405. 
9. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ and 
Pennell DJ. Differentiation of heart failure related to dilated cardiomyopathy and coronary 
artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 
2003;108:54-59. 
10. Assomull RG, Shakespeare C, Kalra PR, Lloyd G, Gulati A, Strange J, Bradlow WM, 
Lyne J, Keegan J, Poole-Wilson P, Cowie MR, Pennell DJ and Prasad SK. Role of 
cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in 
patients presenting with heart failure of unknown etiology. Circulation. 2011;124:1351-1360. 
11. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, 
Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Hlatky MA, Granger CB, Hammill 
SC, Joglar JA, Kay GN, Matlock DD, Myerburg RJ and Page RL. 2017 aha/acc/hrs guideline 
for management of patients with ventricular arrhythmias and the prevention of sudden 
cardiac death: Executive summary: A report of the american college of cardiology/american 
Gulati et al: Fibrosis in New-Onset HF  
20  
heart association task force on clinical practice guidelines and the heart rhythm society. 
Circulation. 2017. doi: 10.1161/CIR.0000000000000549. [Epub ahead of print] 
12. Kwong RY, Chan AK, Brown KA, Chan CW, Reynolds HG, Tsang S and Davis RB. 
Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on 
event-free survival in patients presenting with signs or symptoms of coronary artery disease. 
Circulation. 2006;113:2733-2743. 
13. Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly 
TA, Lloyd-Jones D, Klocke FJ and Bonow RO. Infarct size by contrast enhanced cardiac 
magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction 
or end-systolic volume index: Prospective cohort study. Heart. 2008;94:730-736. 
14. Cheong BY, Muthupillai R, Wilson JM, Sung A, Huber S, Amin S, Elayda MA, Lee 
VV and Flamm SD. Prognostic significance of delayed-enhancement magnetic resonance 
imaging: Survival of 857 patients with and without left ventricular dysfunction. Circulation. 
2009;120:2069-2076. 
15. Kancharla K, Weissman G, Elagha AA, Kancherla K, Samineni S, Hill PC, Boyce S 
and Fuisz AR. Scar quantification by cardiovascular magnetic resonance as an independent 
predictor of long-term survival in patients with ischemic heart failure treated by coronary 
artery bypass graft surgery. J Cardiovasc Magn Reson. 2016;18:45. 
16. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, 
Poole-Wilson PA and Pennell DJ. Cardiovascular magnetic resonance, fibrosis, and 
prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985. 
17. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke 
DA, Gerstenblith G, Marbán E, Tomaselli GF and Lima JAC. Late gadolinium enhancement 
by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic 
cardiomyopathy. J Am Coll Cardiol. 2008;51:2414-2421. 
Gulati et al: Fibrosis in New-Onset HF  
21  
18. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, 
Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O'Hanlon R, 
Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ 
and Prasad SK. Association of fibrosis with mortality and sudden cardiac death in patients 
with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908. 
19. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, 
Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, 
Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, 
Pennell DJ and Prasad SK. Association between midwall late gadolinium enhancement and 
sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left 
ventricular systolic dysfunction. Circulation. 2017;135:2106-2115. 
20. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, 
Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW and 
Yancy CW. 2009 focused update incorporated into the acc/aha 2005 guidelines for the 
diagnosis and management of heart failure in adults: A report of the american college of 
cardiology foundation/american heart association task force on practice guidelines developed 
in collaboration with the international society for heart and lung transplantation. Circulation. 
2009;119:e391-e479. 
21. Felker GM, Shaw LK and O'Connor CM. A standardized definition of ischemic 
cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39:210-218. 
22. Maceira AM, Prasad SK, Khan M and Pennell DJ. Normalized left ventricular 
systolic and diastolic function by steady state free precession cardiovascular magnetic 
resonance. J Cardiovasc Magn Reson. 2006;8:417-426. 
Gulati et al: Fibrosis in New-Onset HF  
22  
23. Maceira AM, Prasad SK, Khan M and Pennell DJ. Reference right ventricular systolic 
and diastolic function normalized to age, gender and body surface area from steady-state free 
precession cardiovascular magnetic resonance. European Heart Journal. 2006;27:2879-2888. 
24. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni 
M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F, Cowie 
MR, McKenna WJ, Sheppard MN, Elliott PM, Pennell DJ and Prasad SK. Prognostic 
significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 
2010;56:867-874. 
25. Disertori M, Rigoni M, Pace N, Casolo G, Mase M, Gonzini L, Lucci D, Nollo G and 
Ravelli F. Myocardial fibrosis assessment by lge is a powerful predictor of ventricular 
tachyarrhythmias in ischemic and nonischemic lv dysfunction: A meta-analysis. JACC 
Cardiovasc Imaging. 2016;9:1046-1055. 
26. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM and Salerno M. Late 
gadolinium enhancement on cmr predicts adverse cardiovascular outcomes in non-ischemic 
cardiomyopathy: A systematic review and meta-analysis. Circ Cardiovasc Imaging. 2013. 
27. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM 
and Vasan RS. Long-term trends in the incidence of and survival with heart failure. N Engl J 
Med. 2002;347:1397-1402. 
28. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A and Grobbee 
DE. The prognosis of heart failure in the general population: The rotterdam study. Eur Heart 
J. 2001;22:1318-1327. 
29. Bui AL, Horwich TB and Fonarow GC. Epidemiology and risk profile of heart 
failure. Nat Rev Cardiol. 2011;8:30-41. 
30. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, Drazner MH, 
Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, 
Gulati et al: Fibrosis in New-Onset HF  
23  
McBride PE, Peterson PN, Stevenson LW and Westlake C. 2017 acc/aha/hfsa focused update 
of the 2013 accf/aha guideline for the management of heart failure: A report of the american 
college of cardiology/american heart association task force on clinical practice guidelines and 
the heart failure society of america. Circulation. 2017;136:e137-e161. 
31. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, 
Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, 
Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH and van 
der Meer P. 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart 
failure. Eur Heart J. 2016;37:2129-200. 
32. Teeter WA, Thibodeau JT, Rao K, Brickner ME, Toto KH, Nelson LL, Mishkin JD, 
Ayers CR, Miller JG, Mammen PP, Patel PC, Markham DW and Drazner MH. The natural 
history of new-onset heart failure with a severely depressed left ventricular ejection fraction: 
Implications for timing of implantable cardioverter-defibrillator implantation. Am Heart J. 
2012;164:358-364. 
33. Voskoboinik A, Bloom J, Taylor A and Mariani J. Early implantation of primary 
prevention implantable cardioverter defibrillators for patients with newly diagnosed severe 
nonischemic cardiomyopathy. Pacing Clin Electrophysiol. 2016;39:992-998. 
34. Masci PG, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S, Todiere G, 
Srebot V, Passino C, Aquaro GD, Emdin M and Lombardi M. Myocardial fibrosis as a key 
determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: A contrast-
enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013;6:790-799. 
35. Bello D, Shah DJ, Farah GM, Di Luzio S, Parker M, Johnson MR, Cotts WG, Klocke 
FJ, Bonow RO, Judd RM, Gheorghiade M and Kim RJ. Gadolinium cardiovascular magnetic 
resonance predicts reversible myocardial dysfunction and remodeling in patients with heart 
failure undergoing beta-blocker therapy. Circulation. 2003;108:1945-1953. 
Gulati et al: Fibrosis in New-Onset HF  
24  
36. Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, Sullivan T, 
Worthley SG, De Pasquale CG, Sanders P and Selvanayagam JB. Effects of myocardial 
fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic 
dilated cardiomyopathy: Insights from cardiovascular magnetic resonance and 
echocardiography. Eur Heart J. 2012;33:640-648. 
37. Romero J, Xue X, Gonzalez W and Garcia MJ. Cmr imaging assessing viability in 
patients with chronic ventricular dysfunction due to coronary artery disease: A meta-analysis 
of prospective trials. JACC Cardiovasc Imaging. 2012;5:494-508. 
38. Bilchick KC, Kuruvilla S, Hamirani YS, Ramachandran R, Clarke SA, Parker KM, 
Stukenborg GJ, Mason P, Ferguson JD, Moorman JR, Malhotra R, Mangrum JM, Darby AE, 
Dimarco J, Holmes JW, Salerno M, Kramer CM and Epstein FH. Impact of mechanical 
activation, scar, and electrical timing on cardiac resynchronization therapy response and 
clinical outcomes. J Am Coll Cardiol. 2014;63:1657-1666. 
39. Hsia HH and Marchlinski FE. Electrophysiology studies in patients with dilated 
cardiomyopathies. Card Electrophysiol Rev. 2002;6:472-481. 
40. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM and Taylor AJ. 
Myocardial fibrosis predicts appropriate device therapy in patients with implantable 
cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 
2011;57:821-828. 
41. Venero JV, Doyle M, Shah M, Rathi VK, Yamrozik JA, Williams RB, Vido DA, 
Rayarao G, Benza R, Murali S, Glass J, Olson P, Sokos G and Biederman RWW. Mid wall 
fibrosis on cmr with late gadolinium enhancement may predict prognosis for lvad and 
transplantation risk in patients with newly diagnosed dilated cardiomyopathy-preliminary 
observations from a high-volume transplant centre. ESC Heart Fail. 2015;2:150-159. 
Gulati et al: Fibrosis in New-Onset HF  
25  
42. Muller KA, Muller I, Kramer U, Kandolf R, Gawaz M, Bauer A and Zuern CS. 
Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with 
newly diagnosed non-ischemic cardiomyopathy: Cohort study. PLoS One. 2013;8:e57077. 
43. Poyhonen P, Kivisto S, Holmstrom M and Hanninen H. Quantifying late gadolinium 
enhancement on cmr provides additional prognostic information in early risk-stratification of 
nonischemic cardiomyopathy: A cohort study. BMC Cardiovasc Disord. 2014;14:110. 
44. Japp AG, Gulati A, Cook SA, Cowie MR and Prasad SK. The diagnosis and 
evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67:2996-3010. 
45. Leyva F, Taylor RJ, Foley PW, Umar F, Mulligan LJ, Patel K, Stegemann B, Haddad 
T, Smith RE and Prasad SK. Left ventricular midwall fibrosis as a predictor of mortality and 
morbidity after cardiac resynchronization therapy in patients with nonischemic 
cardiomyopathy. J Am Coll Cardiol. 2012;60:1659-1667. 
46. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Jensen G, 
Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson 
F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C and 
Pehrson S. Defibrillator implantation in patients with nonischemic systolic heart failure. N 
Engl J Med. 2016;375:1221-1230. 
47. McMurray JJ. The icd in heart failure - time for a rethink? N Engl J Med. 
2016;375:1283-1284. 
48. Selvanayagam JB, Hartshorne T, Billot L, Grover S, Hillis GS, Jung W, Krum H, 
Prasad S and McGavigan AD. Cardiovascular magnetic resonance-guided management of 
mild to moderate left ventricular systolic dysfunction (cmr guide): Study protocol for a 
randomized controlled trial. Ann Noninvasive Electrocardiol. 2017;22. 
Gulati et al: Fibrosis in New-Onset HF  
26  
TABLE LEGENDS 
 
Table 1. Baseline Characteristics of the Study Group According to Fibrosis Pattern. 
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II-receptor blocker; CAD, 
coronary artery disease; HF, heart failure; LV, left ventricular; LVEDV, left ventricular end-
diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-
systolic volume; NYHA, New York Heart Association; RV, right ventricular; RVEDV, right 
ventricular end-diastolic volume; RVEF, right ventricular ejection fraction; RVESV, right 
ventricular end-systolic volume.  
*Variable was not normally distributed and is presented as median (upper quartile, lower 
quartile). 
 
Table 2. Study Outcome Data According to Fibrosis Pattern. 
HF denotes heart failure. 
*The number of patients who experienced an index composite outcome is stated. 
 
Table 3. Hazard Ratios for All-Cause Mortality in Univariable Analysis. 
CAD indicates coronary artery disease; CI, confidence interval; LV, left ventricular; 
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; 
LVESV, left ventricular end-systolic volume; NYHA, New York Heart Association; RV, 
right ventricular; RVEDV, right ventricular end-diastolic volume; RVEF, right ventricular 
ejection fraction; RVESV, right ventricular end-systolic volume. 
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Table 4. Hazard Ratios for Primary and Secondary End Points in Multivariable 
Analysis 
*In multivariable model 1, fibrosis pattern was included as a covariable.  
†In multivariable model 2, fibrosis percentage extent was included as a covariable.  
CI indicates confidence interval; HF, heart failure; SCD, sudden cardiac death; LVEF, left 
ventricular ejection fraction. 
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FIGURE LEGENDS 
 
Figure 1. Fibrosis Patterns Identified by Late Gadolinium Enhancement 
Cardiovascular Magnetic Resonance in Patients with New-Onset Heart Failure. A&B: 
Subendocardial late gadolinium enhancement (LGE) in the lateral and inferior walls 
indicating infarct fibrosis. C&D: Midwall LGE of the septum indicating midwall fibrosis. 
E&F: No LGE in a patient with no detectable replacement fibrosis.      
 
Figure 2. Kaplan-Meier Estimates of the time to All-Cause Mortality (A), 
Cardiovascular Death or Aborted Sudden Cardiac Death (B), and All-Cause Mortality, 
Heart Failure Hospitalization or Aborted Sudden Cardiac Death (C), According to 
Fibrosis Pattern. 
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TABLES  
 
Table 1. 
 
  All patients Infarct fibrosis Midwall fibrosis No fibrosis   
Characteristics (n=120) (n=31) (n=25) (n=64) P value 
Age,yr 56.8±11.2 59.8±10.6 53.2±11.7 56.8±11.0 0.087 
Male sex,n(%) 96 (80.0) 29 (93.6) 21 (84.0) 46 (71.9) 0.035 
HF duration,days* 59 (34,88) 46 (15,75) 50 (30,93) 65 (42,94) 0.07 
Diabetes,n(%) 20 (16.7) 9 (29.0) 2 (8.0) 9 (14.1) 0.099 
Hypertension,n(%) 56 (46.7) 19 (61.3) 5 (20.0) 32 (50.0) 0.006 
Hypercholesterolemia,n(%) 37 (30.8) 13 (41.9) 7 (28.0) 17 (26.6) 0.33 
Smoker,n(%) 29 (24.2) 11 (35.5) 3 (12.0) 15 (23.4) 0.13 
Flu/coryzal symptoms,n(%) 11 (9.2) 3 (9.7) 2 (8.0) 6 (9.4) 1.00 
History of alcohol excess,n(%) 7 (5.8) 1 (3.2) 2 (8.0) 4 (6.3) 0.88 
Significant CAD,n(%) 27 (22.5) 23 (74.2) 1 (4.0) 3 (4.7) <0.001 
NYHA functional class,n(%)           
 I 29 (24.2) 7 (22.6) 10 (40.0) 12 (18.8) 0.13 
 II 75 (62.5) 17 (54.8) 13 (52.0) 45 (70.3) 
  III 16 (13.3) 7 (22.6) 2 (8.0) 7 (10.9)   
Medications at baseline,n(%)           
Aspirin 56 (46.7) 20 (64.5) 15 (60.0) 21 (32.8) 0.004 
Warfarin 11 (9.2) 2 (6.5) 4 (16.0) 5 (7.8) 0.44 
Beta-blocker 84 (70.0) 21 (67.7) 18 (72.0) 45 (70.3) 0.93 
ACE-inhibitor or ARB 110 (91.7) 29 (93.6) 22 (88.0) 59 (92.2) 0.75 
Statin 56 (46.7) 20 (64.5) 12 (48.0) 24 (37.5) 0.048 
Loop diuretic 73 (60.8) 20 (64.5) 17 (68.0) 36 (56.3) 0.56 
Aldosterone antagonist 24 (20.0) 7 (22.6) 7 (28.0) 10 (15.6) 0.36 
Cardiovascular Magnetic Resonance measurements           
LVEDV index,ml/m2 124.0±43.5 128.3±56.9 137.1±47.1 116.7±32.4 0.22 
LVESV index,ml/m2 80.3±44.8 85.8±58.7 94.2±47.4 72.3±33.8 0.11 
LV stroke volume,ml 87.3±29.1 85.0±26.6 85.9±21.6 88.9±32.9 0.90 
LVEF,% 39.0±13.5 37.2±14.2 35.1±12.0 41.3±13.4 0.075 
LV mass index,g/m2 107.6±33.9 103.5±28.9 111.6±41.6 108.0±33.2 0.83 
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RVEDV index,ml/m2 81.0±24.4 80.9±26.7 81.6±23.6 80.8±23.9 0.92 
RVESV index,ml/m2 38.3±20.3 40.3±22.7 40.8±18.3 36.3±20.0 0.22 
RV stroke volume,ml  85.6±27.8 81.3±27.0 81.5±17.7 89.3±31.0 0.24 
RVEF,% 54.4±12.8 51.9±12.7 51.7±9.7 56.6±13.6 0.020 
Fibrosis extent,%*   4.4 (1.5,7.4) 2.4 (1.3,4.3)      
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Table 2. 
 
      All patients Infarct fibrosis Midwall fibrosis No fibrosis 
Outcome (n=120) (n=31) (n=25) (n=64) 
          
Primary end point, n(%)         
All-cause mortality  33 (27.5) 13 (41.9) 10 (40.0) 10 (15.6) 
          
Secondary end points, n(%)         
Cardiovascular death or aborted sudden cardiac death*  27 (22.5) 10 (32.3) 12 (48.0) 5 (7.8) 
Cardiovascular Death 21 (17.5) 9 (29.0) 8 (32.0) 4 (6.3) 
Aborted Sudden Cardiac Death 6 (5.0) 1 (3.2) 4 (16.0) 1 (1.6) 
          
All-cause mortality, HF hospitalization or aborted sudden cardiac death* 43 (36.1) 16 (51.6) 13 (54.2) 14 (21.9) 
Heart failure hospitalisation  20 (16.7) 8 (25.8) 5 (20.0) 7 (10.9) 
          
Device implantation         
Implantable cardioverter-defibrillator 7 (5.8) 3 (9.7) 2 (8.0) 2 (3.1) 
Cardiac resynchronisation therapy without defibrillator 11 (9.2) 2 (6.5) 3 (12.0) 6 (9.4) 
Cardiac resynchronisation therapy with defibrillator  17 (14.2) 4 (12.9) 6 (24.0) 7 (17.2) 
          
Coronary revascularization         
Percutaneous coronary revascularization 9 (7.5) 7 (22.6) 0 (0) 2 (3.1) 
Coronary artery bypass graft surgery 9 (7.5) 8 (25.8) 0 (0) 1 (1.6) 
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Table 3. 
 
 
Univariable Analysis 
 
Unadjusted Hazard Ratio  
 Variable (95% CI) Χ2 P value 
Age,per 10 years increase 1.34 (0.98-1.85) 3.43 0.068 
Male sex  1.52 (0.59-3.93) 0.81 0.39 
Diabetes 1.74 (0.78-3.86) 1.67 0.17 
Hypertension 0.85 (0.42-1.69) 0.23 0.63 
Hypercholesterolemia 1.01 (0.48-2.12) 0.0003 0.99 
Smoker 1.08 (0.49-2.40) 0.04 0.85 
Flu/coryzal symptoms  0.92 (0.28-3.00) 0.02 0.88 
History of alcohol excess  1.75 (0.53-5.75) 0.73 0.36 
Significant CAD 2.16 (1.04-4.45) 3.90 0.038 
NYHA functional class 1.91 (1.04-3.49) 4.42 0.036 
LVEDV index,per 10ml/m2 increase 1.08 (1.01-1.15) 4.40 0.019 
LVESV index,per 10ml/m2 increase 1.09 (1.03-1.15) 6.69 0.003 
LV stroke volume,per 10ml decrease 1.14 (1.00-1.30) 3.93 0.056 
LVEF,per 5% decrease 1.22 (1.07-1.39) 9.55 0.002 
LV mass index,per 10g/m2 increase 1.01 (0.91-1.12) 0.03 0.55 
RVEDV index,per 10ml/m2 increase 0.96 (0.83-1.12) 0.25 0.62 
RVESV index,per 10ml/m2 increase 1.12 (0.97-1.29) 2.04 0.13 
RV stroke volume,per 10ml decrease 1.23 (1.07-1.42) 7.97 0.005 
RVEF,per 5% decrease 1.21 (1.08-1.37) 9.32 0.002 
Fibrosis pattern 
 
 
 No fibrosis 1.00  
 Infarct fibrosis 3.32 (1.46-7.58) 10.33 0.004 
Midwall fibrosis 2.99 (1.24-7.19)  0.014 
Fibrosis extent,per 1% increase  1.07 (1.04-1.11) 11.90 <0.001 
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Table 4. 
 
  
Model 1* 
 
Model 2† 
  
Adjusted Hazard 
Ratio 
  
Adjusted Hazard 
Ratio 
 
Outcome Variable (95% CI) P value 
 
(95% CI) P value 
All-cause mortality  LVEF,per 5% decrease 1.19 (1.05-1.35) 0.006 
 
1.17 (1.03-1.33) 0.017 
 
Age,per 10 years increase 1.38 (0.99-1.94) 0.061 
 
1.47 (1.07-2.02) 0.017 
 Male sex 1.43 (0.51-4.03) 0.50  1.32 (0.48-3.63) 0.59 
 
Fibrosis pattern 
     
 
    No fibrosis 1.00 
  
  
 
    Infarct fibrosis 2.60 (1.08-6.27) 0.033 
 
  
 
    Midwall fibrosis 2.64 (1.08-6.47) 0.034 
 
  
 
Fibrosis extent,per 1% increase 
   
1.07 (1.03-1.12)  <0.001 
       Cardiovascular death or 
aborted SCD LVEF,per 5% decrease 1.27 (1.11-1.45) <0.001 
 
1.28 (1.12-1.47)  <0.001 
 
Age,per 10 years increase 1.25 (0.84-1.85) 0.27 
 
1.19 (0.81-1.75) 0.37 
 Male sex 1.91 (0.63-5.78)  0.25  2.05 (0.61-6.91) 0.25 
 
Fibrosis pattern 
     
 
    No fibrosis 1.00 
  
  
 
    Infarct fibrosis 3.45 (1.20-9.90) 0.022 
 
  
 
    Midwall fibrosis 6.59 (2.26-19.22) <0.001 
 
  
 
Fibrosis extent,per 1% increase 
   
1.06 (1.02-1.10) 0.005 
       All-cause mortality,  
HF hospitalization or 
aborted SCD LVEF,per 5% decrease 1.16 (1.05-1.29) 0.005 
 
1.16 (1.03-1.29)  0.011 
  Age,per 10 years increase 1.23 (0.93-1.64) 0.15 
 
1.28 (0.97-1.68) 0.076 
 Male sex 1.60 (0.64-3.97) 0.31  1.62 (0.66-4.00)  0.29 
 
Fibrosis pattern 
     
 
    No fibrosis 1.00 
  
  
 
    Infarct fibrosis 2.69 (1.26-5.76) 0.011 
 
  
 
    Midwall fibrosis 2.97 (1.37-6.45) 0.006 
 
  
 
Fibrosis extent,per 1% increase 
   
1.05 (1.01-1.09)  0.008 
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Table I. Hazard Ratios for All-Cause Mortality in Multivariable Analysis including Coronary 
Revascularization (A) or Device Implantation (B) as Candidate Variables 
 
A 
  
Model 1* Model 2† 
  
Adjusted Hazard Ratio 
 
Adjusted Hazard Ratio 
 Outcome Variable (95% CI) P value (95% CI) P value 
All-cause mortality  LVEF, per 5% decrease 1.21 (1.07, 1.36) 0.002 1.19 (1.06, 1.33) 0.004 
 
Age, per 10 years increase 1.37 (0.94, 1.98) 0.10 1.63 (1.12, 2.37) 0.011 
 Male sex 1.50 (0.55, 4.14) 0.43 1.60 (0.63, 4.08) 0.32 
 Coronary Revascularization 0.31 (0.08, 1.20) 0.091 0.28 (0.07, 1.15) 0.078 
 
Fibrosis pattern 
    
 
    No fibrosis 1 
 
  
 
    Infarct fibrosis 2.53 (1.09, 5.90) 0.031   
 
    Midwall fibrosis 4.15 (1.58, 10.88) 0.004   
 
Fibrosis extent, per 1% increase 
  
1.10 (1.06, 1.13) <0.0001 
 
 
B 
  
Model 1* Model 2† 
  
Adjusted Hazard Ratio 
 
Adjusted Hazard Ratio 
 Outcome Variable (95% CI) P value (95% CI) P value 
All-cause mortality  LVEF, per 5% decrease 1.18 (1.05, 1.32) 0.005 1.16 (1.03, 1.31) 0.012 
 
Age, per 10 years increase 1.36 (0.94, 1.97) 0.098 1.45 (1.02, 2.07) 0.039 
 Male sex 1.38 (0.48, 3.94) 0.55 1.29 (0.51, 3.27) 0.59 
 ICD/CRT implantation 1.36 (0.62, 2.98) 0.44 1.33 (0.64, 2.76) 0.44 
 
Fibrosis pattern 
    
 
    No fibrosis 1 
 
  
 
    Infarct fibrosis 2.49 (1.03, 5.96) 0.041   
 
    Midwall fibrosis 2.57 (1.05, 6.25) 0.038   
 
Fibrosis extent, per 1% increase 
  
1.07 (1.03, 1.12) 0.001 
 
 
* In multivariable model 1, fibrosis pattern was included as a covariable.  
† In multivariable model 2, fibrosis percentage extent was included as a covariable.  
 
CI indicates confidence interval; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter 
defibrillator; LVEF, left ventricular ejection fraction.  
3 
 
Figure I. Kaplan-Meier Estimates of the time to All-Cause Mortality (A), Cardiovascular Death or 
Aborted Sudden Cardiac Death (B), and All-Cause Mortality, Heart Failure Hospitalization or 
Aborted Sudden Cardiac Death (C), stratified by Fibrosis Pattern after adjustment for Age, Sex, 
and Left Ventricular Ejection Fraction. 
 
 
